H.C. Wainwright lowered the firm’s price target on Intellia Therapeutics (NTLA) to $25 from $30 and keeps a Buy rating on the shares. The firm cites dilution from the recent financing for the target cut.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- FDA Commissioner Marty Makary resigns
- Intellia Therapeutics price target lowered to $19 from $20 at BofA
- Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
- Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)
- Myles Minter Reiterates Buy on Intellia (NTLA), Citing Extended Cash Runway and Strong Phase III Data for Lonvoguran Ziclumeran